Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients with Atrial Fibrillation.

We investigated the incidence of non-embolic adverse events in 2 cohorts of AF patients and validated the 2MACE score [(metabolic syndrome, age ≥75) [doubled]; (myocardial infarction (MI)/revascularization, congestive heart failure (HF) and stroke/TIA/thromboembolism)] as predictor of major adverse cardiovascular events (MACEs). We recruited 2630 AF patients from two different cohorts (Murcia AF and FANTASIIA). The 2MACE score was calcula ted and during a median of 7.2 years (Murcia AF cohort) and 1.01 years (FANTASIIA) of follow-up we recorded all non-embolic adverse events and MACEs (composite of non-fatal MI/revascularization and cardiovascular death).

Source: The American Journal of Cardiology - September 18, 2017 Category: Cardiology Authors: Jos é Miguel Rivera-Caravaca, Francisco Marín, María Asunción Esteve-Pastor, Paula Raña-Míguez, Manuel Anguita, Javier Muñiz, Ángel Cequier, Vicente Bertomeu-Martínez, Mariano Valdés, Vicente Vicente, Gregory Yoke Hong Lip, Vanessa Roldán Source Type: research